KR20230117581A - 펩티드 수용체 방사성 핵종 요법 - Google Patents
펩티드 수용체 방사성 핵종 요법 Download PDFInfo
- Publication number
- KR20230117581A KR20230117581A KR1020237020941A KR20237020941A KR20230117581A KR 20230117581 A KR20230117581 A KR 20230117581A KR 1020237020941 A KR1020237020941 A KR 1020237020941A KR 20237020941 A KR20237020941 A KR 20237020941A KR 20230117581 A KR20230117581 A KR 20230117581A
- Authority
- KR
- South Korea
- Prior art keywords
- conjugate
- peg
- peg moiety
- mci
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121762P | 2020-12-04 | 2020-12-04 | |
| US63/121,762 | 2020-12-04 | ||
| PCT/US2021/061886 WO2022120226A1 (en) | 2020-12-04 | 2021-12-03 | Peptide receptor radionuclide therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230117581A true KR20230117581A (ko) | 2023-08-08 |
Family
ID=81853616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237020941A Pending KR20230117581A (ko) | 2020-12-04 | 2021-12-03 | 펩티드 수용체 방사성 핵종 요법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240131206A1 (https=) |
| EP (1) | EP4255891A4 (https=) |
| JP (1) | JP2023552383A (https=) |
| KR (1) | KR20230117581A (https=) |
| CN (1) | CN116829541A (https=) |
| AU (1) | AU2021390552A1 (https=) |
| CA (1) | CA3203175A1 (https=) |
| MX (1) | MX2023006483A (https=) |
| WO (1) | WO2022120226A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025160502A1 (en) | 2024-01-26 | 2025-07-31 | The Regents Of The University Of California | Peptide receptor radionuclide therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0282057A3 (en) * | 1987-03-11 | 1990-03-07 | The Board Of Regents Of The University Of Michigan | Chemo-radio-immuno-conjugates |
| MX340566B (es) * | 2007-03-27 | 2016-07-14 | Radiomedix Inc | Composiciones para formacion de imagen objetivo y terapia. |
| US20120015899A1 (en) * | 2008-10-25 | 2012-01-19 | Plant Bioscience, Limited | Modified plant virus particles and uses therefor |
| WO2011082191A1 (en) * | 2009-12-30 | 2011-07-07 | Ge Healthcare Limited | Method of using a 99mtc-labelled injection rgd compound and a [18f]-labelled rgd injection compound in external beam radiotherapy planning |
| CA2945945C (en) * | 2014-04-15 | 2023-10-03 | The Regents Of The University Of California | Bi-terminal pegylated integrin-binding peptides and methods of use thereof |
| EP3468984A4 (en) * | 2016-06-13 | 2020-03-11 | The Regents of the University of California | ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF |
| MX2019005742A (es) * | 2016-11-23 | 2019-09-13 | Cancer Targeted Tech Llc | Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. |
| GB201706472D0 (en) * | 2017-04-24 | 2017-06-07 | Cancer Res Tech Ltd | Tumour-targeting peptide variants |
| CN111032632B (zh) * | 2017-05-30 | 2024-04-12 | 约翰霍普金斯大学 | 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 |
| CN109091683B (zh) * | 2018-08-10 | 2019-10-18 | 北京大学 | 一种用于整合素αvβ6靶向的环状多肽放射性药物及其制备方法 |
| WO2021226432A2 (en) * | 2020-05-08 | 2021-11-11 | The Regents Of The University Of California | Methods of detecting and treating lung damage in respiratory-related viral infections |
-
2021
- 2021-12-03 AU AU2021390552A patent/AU2021390552A1/en active Pending
- 2021-12-03 WO PCT/US2021/061886 patent/WO2022120226A1/en not_active Ceased
- 2021-12-03 US US18/038,851 patent/US20240131206A1/en active Pending
- 2021-12-03 MX MX2023006483A patent/MX2023006483A/es unknown
- 2021-12-03 JP JP2023533889A patent/JP2023552383A/ja active Pending
- 2021-12-03 KR KR1020237020941A patent/KR20230117581A/ko active Pending
- 2021-12-03 EP EP21901568.2A patent/EP4255891A4/en active Pending
- 2021-12-03 CN CN202180092891.6A patent/CN116829541A/zh active Pending
- 2021-12-03 CA CA3203175A patent/CA3203175A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022120226A1 (en) | 2022-06-09 |
| CN116829541A (zh) | 2023-09-29 |
| EP4255891A4 (en) | 2026-03-18 |
| AU2021390552A9 (en) | 2024-06-20 |
| AU2021390552A1 (en) | 2023-06-29 |
| CA3203175A1 (en) | 2022-06-09 |
| US20240131206A1 (en) | 2024-04-25 |
| JP2023552383A (ja) | 2023-12-15 |
| EP4255891A1 (en) | 2023-10-11 |
| MX2023006483A (es) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12605447B2 (en) | Stable formulations for radionuclide complexes | |
| KR102934560B1 (ko) | 신장 보호 물질로서의 파라-아미노히푸르산(pah) | |
| Zhang et al. | Biodistribution and localization of iodine-131 labeled Metuximab in patients with hepatocellular carcinoma | |
| KR20220006286A (ko) | 전립선암 진단 및 치료를 위한 전립선특이 막 항원 표적 화합물 및 이를 포함하는 전립선암 진단 및 치료용 조성물 | |
| Chen et al. | In vivo examination of 188Re (I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer | |
| KR20230117581A (ko) | 펩티드 수용체 방사성 핵종 요법 | |
| US20240342322A1 (en) | Netrin-1 detection, companion test and therapy based on radiations | |
| KR20260040237A (ko) | Psma 표적 방사성 리간드 치료 요법 | |
| US20240050597A1 (en) | Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent | |
| CN118891066A (zh) | 用于癌症治疗和成像的复合物 | |
| HK40103039A (zh) | 肽受体放射性核素治疗 | |
| WO2025160502A1 (en) | Peptide receptor radionuclide therapy | |
| RU2804349C2 (ru) | Парааминогиппуровая кислота (паг) как вещество для защиты почек | |
| WO2026083399A1 (en) | Conjugates and use of same for theranostics | |
| CB et al. | Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease | |
| Ahmad | The Use of Bioorthogonal Chemistry to Create 99mTc and Micelle-based Diagnostic Agents | |
| WO2026050761A1 (en) | Noninvasive tracking of a targeted toxin | |
| CN122003254A (zh) | 用于诊断和/或治疗神经内分泌癌的方法 | |
| Class et al. | Patent application title: COMPOSITIONS AND METHODS FOR THE PREPARATION OF KIDNEY PROTECTIVE AGENTS COMPRISING AMIFOSTINE AND AMINO ACIDS Inventors: Ebrahim Delpassand (Houston, TX, US) Izabela Tworowska (Houston, TX, US) Sanjay Thamake (Houston, TX, US) David Ranganathan (Houston, TX, US) | |
| JP2015083546A (ja) | 癌の原発巣・骨転移の検査・治療用放射性標識薬剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230621 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20241202 Comment text: Request for Examination of Application |